"We set out nearly three years ago to create a cutting-edge AI solution that empowers clinicians to make faster, more accurate decisions on radiology diagnosis. With the hard work of our global team, we've built an extremely strong and sustainable business with a proven model and global roadmap," said annalise.ai founding CEO and board director Dimitry Tran.
"To truly achieve our goals, and grow globally, we must move into the next phase of our maturity and strategy. I'm excited to welcome Mr Gudapakkam and Dr Abramson to the annalise.ai team to lead the company through this next phase of expansion and to help deliver on our mission to help one million people every day."
Gudapakkam brings 30 years' experience to annalise.ai.
He joins the company from Quest Diagnostics, where he worked as vice president and regional general manager.
Gudapakkam previously worked for Philips (most recently as leader of the company's X-ray based businesses), and for GE Healthcare IT (most recently as vice president and global general manager of engineering).
"To meet the growing demands on our global healthcare system, we need smart tools that help specialists diagnose and treat patients more effectively and accurately. The team at annalise.ai have shown an astounding ability to not only provide this capability quickly, but do so with clinical experts and patients at the forefront. I'm excited to join the team and contribute to achieving our goal of helping one million patients every day," said Gudapakkam.
Abramson, a board-certified radiologist, brings more than 25 years of healthcare experience to annalise.ai.
He previously worked as chief clinical strategy officer at Covera Health, corporate vice president of radiology at HCA Healthcare, associate professor of radiology at Vanderbuilt University Medical Center.
He also co-founded Partners in the Imaging Enterprise, worked as an associate at McKinsey & Co and as senior manager at Avalere Health, and interned at Brigham and Women's Hospital.
Abramson holds a bachelor's degree in government from Harvard, a master's in health care delivery science from the Tuck School of Business at Dartmouth College, and an MD from Harvard Medical School.
Both Gudapakkam and Abramson will be based in the US.
Tran will continue to serve as director of the board and part of the harrison.ai team, while harrison.ai co-founder and CEO will also continue as annalise.ai's chief AI officer.
"Dimitry's contribution to annalise.ai cannot be overstated, having tirelessly shepherded the formation and growth of annalise.ai from the beginning. We're delighted that he will continue to have crucial input in the future of annalise.ai as a director of the board," said annalise.ai chair Clare Battellino.
Annalise Enterprise CXR, said to be the world's first comprehensive decision-support AI solution for chest X-rays, is already in clinical use at over 400 sites in Australia and the UK, and has also been cleared for clinical use in Europe, South-East Asia, and New Zealand.
